Juno Therapeutics (JUNO) Misses Q1 EPS by 26c

FREE Breaking News Alerts from StreetInsider.com!

StreetInsider.com Top Tickers, 10/12/2026

1. SPY
2. PLTR
3. MSFT
4. TMUS
5. LBRX

6. BMY
7. MRK
8. TRAX
9. LMT
10. MIRM

Juno Therapeutics Reports First Quarter 2016 Financial Results

May 9, 2016 4:10 PM EDT

-- Strong cash position of $1.13 billion --

-- 2016 cash burn and operating burn guidance reaffirmed --

-- In April, Celgene exercised opt-in right for the CD19 program --

-- Encouraging early clinical trial data for CD22 and WT-1 --

-- JuMP manufacturing facility operational for JCAR015 Phase II ROCKET trial --

-- Conference call to be held today at 5:00pm Eastern Time --

SEATTLE--(BUSINESS WIRE)-- Juno Therapeutics, Inc. (NASDAQ: JUNO), a... More